Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer
October 12, 2017 01:02 ET
|
Targovax ASA
Oslo, Norway, 11 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
October 03, 2017 08:49 ET
|
Targovax ASA
Extends IP protection of TG02 in the US until 09.12.2034 Oslo, 3 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology...
Targovax granted US Patent for mutant-RAS neoantigen platform lead products
September 25, 2017 01:00 ET
|
Targovax ASA
Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology...
Targovax Receives 2017 Nordic Stars Award
September 14, 2017 10:01 ET
|
Targovax ASA
Oslo, Norway, 14 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
September 12, 2017 09:49 ET
|
Targovax ASA
Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start...
Targovax ASA: Three posters presented at ESMO conference
September 11, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today...
Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
August 29, 2017 04:03 ET
|
Targovax ASA
Reference is made to the stock exchange notice of 18 August 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the...
Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
August 28, 2017 01:02 ET
|
Targovax ASA
1. Settlement of vested restricted stock units ("RSUs") Robert Burns, member of the board of directors of Targovax ASA (the "Primary Insider"), has on 25 August 2017 subscribed for 40,984...
Exercise of employee share options and restricted stock units in Targovax ASA
August 25, 2017 07:03 ET
|
Targovax ASA
Reference is made to the stock exchange notice of 18 August 2017 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...
Targovax ASA: Second quarter and first half 2017 results
August 24, 2017 01:02 ET
|
Targovax ASA
Oslo, Norway, 24 August 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its second quarter and first...